Levodopa/Carbidopa Intestinal Gel Long-Term Outcome in Parkinson's Disease: Focus on Dyskinesia.
Parkinson's disease
dyskinesia
gender
levodopa/carbidopa intestinal gel
Journal
Movement disorders clinical practice
ISSN: 2330-1619
Titre abrégé: Mov Disord Clin Pract
Pays: United States
ID NLM: 101630279
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
28
03
2020
revised:
03
07
2020
accepted:
07
08
2020
entrez:
9
11
2020
pubmed:
10
11
2020
medline:
10
11
2020
Statut:
epublish
Résumé
Levodopa-carbidopa intestinal gel (LCIG) treatment has shown variable effect on dyskinesia in Parkinson's disease (PD). To identify PD patients who are likely to have troublesome dyskinesia under LCIG treatment and describe the pharmacokinetic-dynamic profile and dyskinesia phenomenology of those patients. PD patients were assessed for clinical and therapeutic variables, before LCIG treatment ( We included 53 PD patients. After a mean of 51.7 ± 34.1 months of LCIG treatment, "off-time" was significantly reduced, whereas, dyskinesia duration/disability did not change. The multivariate regression model, adjusted for LCIG treatment duration, showed that being female increases the risk of presenting troublesome dyskinesia at Dyskinesia should be carefully monitored in patients undergoing LCIG, with particular caution for female patients. Whether combined clinical and pharmacodynamic assessments could be helpful to manage patients with troublesome dyskinesia under LCIG treatment needs further evaluation in a larger group of patients.
Sections du résumé
BACKGROUND
BACKGROUND
Levodopa-carbidopa intestinal gel (LCIG) treatment has shown variable effect on dyskinesia in Parkinson's disease (PD).
OBJECTIVE
OBJECTIVE
To identify PD patients who are likely to have troublesome dyskinesia under LCIG treatment and describe the pharmacokinetic-dynamic profile and dyskinesia phenomenology of those patients.
METHODS
METHODS
PD patients were assessed for clinical and therapeutic variables, before LCIG treatment (
RESULTS
RESULTS
We included 53 PD patients. After a mean of 51.7 ± 34.1 months of LCIG treatment, "off-time" was significantly reduced, whereas, dyskinesia duration/disability did not change. The multivariate regression model, adjusted for LCIG treatment duration, showed that being female increases the risk of presenting troublesome dyskinesia at
CONCLUSION
CONCLUSIONS
Dyskinesia should be carefully monitored in patients undergoing LCIG, with particular caution for female patients. Whether combined clinical and pharmacodynamic assessments could be helpful to manage patients with troublesome dyskinesia under LCIG treatment needs further evaluation in a larger group of patients.
Identifiants
pubmed: 33163564
doi: 10.1002/mdc3.13068
pii: MDC313068
pmc: PMC7604637
doi:
Types de publication
Journal Article
Langues
eng
Pagination
930-939Informations de copyright
© 2020 International Parkinson and Movement Disorder Society.
Déclaration de conflit d'intérêts
The study had no specific funding. The authors report no conflict of interest.
Références
Neurodegener Dis Manag. 2019 Feb;9(1):39-46
pubmed: 30547712
Mov Disord. 2016 Apr;31(4):530-7
pubmed: 26817533
Ann Neurol. 2018 Dec;84(6):797-811
pubmed: 30357892
Nat Rev Neurol. 2019 Apr;15(4):234-242
pubmed: 30778210
Neurology. 1998 Oct;51(4):1075-80
pubmed: 9781532
Mov Disord. 2012 Sep 1;27(10):1239-42
pubmed: 22886777
Mov Disord. 2017 Dec;32(12):1701-1709
pubmed: 28833562
Mov Disord. 2015 Oct;30(12):1591-601
pubmed: 26474316
Neurology. 2014 Jan 28;82(4):300-7
pubmed: 24371304
Mov Disord. 2018 Jul;33(6):928-936
pubmed: 29570853
Mov Disord. 2010 Jul 15;25(9):1131-42
pubmed: 20310033
Parkinsonism Relat Disord. 2015 Aug;21(8):871-6
pubmed: 26003410
Mov Disord. 2013 Jul;28(8):1064-71
pubmed: 23630119
Mov Disord. 2017 Apr;32(4):624-625
pubmed: 28116835
Neurology. 2018 Dec 11;91(24):e2238-e2243
pubmed: 30404780
Mov Disord. 2010 Nov 15;25(15):2649-53
pubmed: 21069833
Parkinsonism Relat Disord. 2017 Apr;37:92-96
pubmed: 28063683
Clin Neuropharmacol. 2003 May-Jun;26(3):156-63
pubmed: 12782919
Mov Disord. 2019 Nov;34(11):1747-1748
pubmed: 31603586
Clin Neuropharmacol. 2011 Mar-Apr;34(2):61-5
pubmed: 21297456
Lancet Neurol. 2014 Feb;13(2):141-9
pubmed: 24361112
Parkinsonism Relat Disord. 2019 Dec;69:140-146
pubmed: 31759188
Eur J Neurol. 2019 Mar;26(3):490-496
pubmed: 30347489
Ther Drug Monit. 2001 Dec;23(6):621-9
pubmed: 11802094
Clin Neuropharmacol. 2012 Jan-Feb;35(1):6-14
pubmed: 22094648
Eur J Neurol. 2014 Feb;21(2):312-8
pubmed: 24313838
J Parkinsons Dis. 2019;9(1):173-182
pubmed: 30562907
Brain. 2014 Oct;137(Pt 10):2731-42
pubmed: 25034897
J Parkinsons Dis. 2012;2(3):189-98
pubmed: 23938226
Parkinsonism Relat Disord. 2016 Jan;22:48-53
pubmed: 26585090
J Neurol. 2013 Jan;260(1):105-14
pubmed: 22772358